185
Participants
Start Date
March 23, 2017
Primary Completion Date
March 15, 2019
Study Completion Date
March 15, 2019
Xanamem™
Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
Placebo (for Xanamem™)
Excipient blend capsules manufactured to mimic Xanamem™ capsules
St Vincent's Hospital Sydney, Darlinghurst
KaRa Institute of Neurological Diseases, Macquarie Park
Central Coast Neurosciences Research, Central Coast
Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health, Heidelberg West
Australian Alzheimer's Research Foundation, Nedlands
Richmond Behavioral Associates, Staten Island
The Clinical Trial Center, Jenkintown
PMG Research of Rocky Mount, LLC, Rocky Mount
NeuroStudies.Net, LLC, Decatur
Atlanta Center for Medical Research, Atlanta
Compass Research LLC, Orlando
IMIC, Inc., Palmetto Bay
The Neurology Research Group, LLC, Miami
Research Alliance Inc., Clearwater
Tucson Neuroscience Research, LLC, Tucson
National Research Institute, Los Angeles
PCND Neuroscience Research Institute, Poway
Pacific Research Network, Inc., San Diego
The NeuroCognitive Institute, Mount Arlington
The Research Institute for the Care of Older People, Bath
Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital, Manchester
West London Mental Health Trust, Isleworth
St Pancras Clinical Research, Kings Cross
Institute of Clinical Sciences, Queen's University Belfast, Belfast
Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh, Edinburgh
Lead Sponsor
Collaborators (1)
ICON Clinical Research
INDUSTRY
Actinogen Medical
INDUSTRY